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Abstract 
Background & Objectives: Theory-driven interventions targeting specific factors that 
contribute to delusions are receiving increased interest. The present study aimed to assess the 
efficacy of individualized metacognitive therapy (MCT+), a short manualized intervention that 
addresses delusion-associated cognitive biases. 
Methods: 92 patients with current or past delusions were randomized to receive 12 twice-
weekly sessions of either MCT+ or a control intervention within a randomized controlled rater-
blind design. Psychopathology and cognitive biases were assessed at baseline, 6 weeks and 6 
months. ANCOVAs adjusted for baseline scores were used to assess differences between groups 
regarding outcome variables. Both per-protocol and intention-to-treat analyses were conducted. 
Results: At 6 weeks, there was a significant difference in favor of MCT+ regarding decrease in 
delusion severity and improvement of self-reflectiveness (medium effect size), and a trend-wise 
difference regarding probability threshold to decision. These effects increased, when only 
patients attending a minimum of 4 therapy sessions were considered. Control group patients 
subsequently showed further improvement while patients in the MCT+ group remained stable, 
such that there were no differences between groups at the 6-month follow-up. 
Limitations: Lower attendance rates in the control group possibly leading to unequal 
therapeutic effort; lower baseline delusion severity in the MCT+ group. 
Conclusions: The result pattern suggests that MCT+ led to an earlier improvement in delusions 
and cognitive biases compared to the control intervention. The absence of a long-term effect 
might reflect floor effects in the MCT+ group, but may also indicate the need for further 
measures to promote sustainability of MCT+ effects.  
 
Keywords: schizophrenia, metacognition, cognitive biases, jumping-to-conclusions, 
psychotherapy, cognitive-behavioral therapy.  
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1. Introduction 
Delusions are one of the most common and recognizable symptoms of psychotic disorders. Up 
until the late 20th century, delusional beliefs were viewed as "non-understandable" (Jaspers, 
1913), and biological conceptualizations predominated treatment approaches (Mander and 
Kingdon, 2015). However, a new picture has gradually emerged. Behavioral, cognitive and social 
studies but also social influences such as the consumer movement led to an increased awareness 
of cognitive and psychological factors in the emergence of delusions (Mander and Kingdon, 
2015; Mueser et al., 2013). The concurrent growing realization of the limitations of antipsychotic 
medication, especially with respect to functional recovery (Jaaskelainen et al., 2013; Leucht et 
al., 2009) and adherence issues (Lieberman et al., 2005) have boosted interest in psychological 
interventions for the treatment of delusions.   
Cognitive-behavioral therapy (CBT) has had a leading role in this field. Having provided a wide 
empirical basis supporting its efficacy in treating delusions (Hutton and Taylor, 2014; Turner et 
al., 2014; Wykes et al., 2008), CBT was one of the first psychological interventions to be included 
in treatment guidelines for psychosis. However, there is still an ongoing debate about its 
efficacy,(McKenna and Kingdon, 2014) especially when it comes to disentangling 'true' efficacy 
from unspecific therapy effects (Jauhar et al., 2014; Lynch et al., 2010; Mehl et al., 2015). In an 
effort to maximize efficacy, recent research has focused on targeted therapies that deal with 
individual factors thought to contribute to psychotic symptoms, such as worry (Freeman et al., 
2015) or reasoning biases (Garety et al., 2015; Moritz et al., 2014a; Waller et al., 2011). It has 
been suggested that such theory-driven interventions may lead to improved outcomes 
compared to standard CBT (Mehl et al., 2015). 
One of these refined approaches is metacognitive training (MCT), a manualized group 
intervention (Moritz et al., 2013b). MCT builds upon evidence associating delusional beliefs with 
specific thinking styles that lead to distorted appraisals of events (Garety and Freeman, 2013). 
Well-established examples include jumping-to-conclusions, overconfidence in false judgments, 
and belief inflexibility/incorrigibility. Importantly, these thinking styles, termed 'cognitive 
biases', are not symptom-specific, but rather an extension of normal thinking styles, appearing 
also in neutral (i.e. delusion-unrelated) contexts. MCT adopts a hands-on approach, aiming to 
raise patients' awareness for such cognitive biases. The ultimate goal is to 'plant the seeds of 
doubt' through entertaining and collaborative exercises that use predominantly non-delusional 
scenarios. 
Several randomized controlled studies (Moritz et al., 2014a) as well as a recent meta-analysis 
(Eichner and Berna, 2016) have shown promising results regarding the short- and long-term 
efficacy of group MCT on delusions and/or positive psychotic symptoms in general (although 
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there have also been negative results (van Oosterhout et al., 2014; van Oosterhout et al., 2016)). 
This effect appears to be complementary to that of antipsychotic medication, since all the above 
results were obtained using MCT as adjunctive treatment to patients already receiving 
antipsychotics. However, the group intervention format may not be suited for some patients, 
including those with high level of suspiciousness (van Oosterhout et al., 2014), or patients with 
negative and/or disorganized symptoms that may require more intensive and structured work 
(Moritz et al., 2005). On the other hand, it has been suggested that the effects of metacognitive 
interventions on reasoning and delusions might be promoted with use of personalized material 
and individual therapy sessions (Garety et al., 2015; van Oosterhout et al., 2014).  
Previous studies have shown that use of MCT material in an individual treatment format can 
have beneficial effects on cognitive biases and/or delusions after very few sessions (Balzan et al., 
2014; Balzan and Galletly, 2015; Ross et al., 2011; So et al., 2015; Waller et al., 2011). In a 
randomized, controlled, rater-blind trial of group MCT combined with individualized sessions 
(Moritz et al., 2011), patients in the MCT arm showed significantly greater improvement in 
delusion severity and conviction, as well as in jumping-to-conclusions, relative to the active 
control group. Interestingly, effect sizes were quite large (d>0.6) for delusions in that study 
despite the short duration of the intervention and follow-up (4 weeks). The authors concluded 
that the application of MCT material to individual delusional beliefs might provide additional 
benefits compared to the group MCT; however, the sample size was too small to draw conclusive 
inferences. 
Based on these findings, our group developed a fully individualized version of MCT. 
Metacognitive therapy (MCT+)(Moritz et al., 2012b) is a manualized intervention that, similar to 
MCT, targets common reasoning biases encountered in patients with delusions. However, MCT 
addresses the 'metacognitive infrastructure' of delusions solely with use of neutral exercises. In 
contrast, individualized MCT+ follows up on this initial step by applying the learned material 
(using techniques adopted from CBT) to challenge the content of individual delusional beliefs.   
So far, there have been no randomized clinical studies on MCT+. Therefore, the present study 
aimed to assess the efficacy of this intervention in patients with delusions compared to an active 
control condition, consisting in a cognitive training intervention. We designed the study as a 
randomized controlled, rater-blinded trial, while at the same time including as many 'pragmatic' 
aspects as possible (such as broad inclusion criteria and flexibility in intervention delivery) to 
ensure generalizability of results and inform planning of larger, multicenter trials on MCT+. We 
hypothesized that MCT+ would lead to significantly greater decline in delusion severity and 
dysfunctional reasoning compared to the control condition.  
5 
 
2. Materials and methods 
The study was conducted at the Department of Psychiatry and Psychotherapy of the University 
Medical Center Hamburg-Eppendorf (Germany). Participants were 92 patients with non-
affective psychotic disorders and current or past delusions, recruited among in- and outpatients 
treated at the Psychosis Center of the Department from January 2013 through July 2015 and 
judged by their attending psychiatrist to qualify for study participation. Inclusion criteria were 
age 18 to 65 years, a DSM-IV diagnosis of a schizophrenia spectrum disorder confirmed with the 
Mini Neuropsychiatric Interview (Sheehan et al., 1998), and a present or prior delusional 
episode. Exclusion criteria were kept to a minimum in order to ensure generalizability of 
findings, and included a primary diagnosis of substance use disorder, IQ<70, severe organic 
brain disorders, previous experience with group MCT or any of the experimental interventions, 
and any ongoing CBT-oriented psychotherapy. The trial was approved by the ethics committee 
of the German Psychology Association, and all patients gave their written informed consent 
before entering the study. A CONSORT diagram is provided in Figure 1. 
Patients were randomized according to a computerized randomization plan [pseudorandom 
fixed procedure, analogous to a previous group MTC trial by our group (Moritz et al., 2014b; 
Moritz et al., 2013a)] to one of two interventions: MCT+ or CogPack® (Marker, 2003) (see below 
for details regarding the interventions). Treatment arm allocation was performed observer-
blind and communicated to patients by a person who was neither involved in the assessments 
nor in intervention delivery. All patients continued to receive their usual treatment throughout 
study participation. Importantly, as group MCT is a standard part of treatment in our 
department, patients from both groups were allowed to take part in MCT groups during study 
participation. However, this information was documented and considered in analyses. 
Assessments were carried out at baseline, at 6 weeks (T1, corresponding to completion of 12 
intervention sessions) and 6 months later (T2). All assessments were carried out by raters blind 
to treatment allocation. Rater training was performed according to the same procedure used in 
our recent group MCT study (Moritz et al., 2013a). In order to further enhance reliability, 
assessments for each individual patient were carried out by the same rater throughout the trial 
period.  
2.1 Outcomes 
Psychopathology was assessed with the Psychotic Symptom Rating Scales (PSYRATS) (Haddock 
et al., 1999) and the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987). Both 
instruments have been widely used in intervention studies and have good psychometric 
properties (Drake et al., 2007; Peralta and Cuesta, 1994). The main outcome of interest was 
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delusion severity at T1 as reflected in the delusion subscale total score of the PSYRATS. 
Secondary outcomes included PSYRATS delusion score at T2, PANSS P1 item (Delusions) at T1 
and T2, and psychopathology according to the 5-factor model of the PANSS (Wallwork et al., 
2012), at T1 and T2.  
Further secondary outcomes of interest (assessed both at T1 and T2) included the following: 
― The Fish Task (Moritz et al., 2012a), a computerized variant of the Beads Task, was used to 
assess jumping-to-conclusions, a prototypical cognitive bias. In the task, participants are 
presented with two lakes containing fish in opposite color ratios (80:20 orange:gray or vice-
versa). Ten fish are successively presented in a predetermined sequence to the participant. 
After each draw, the participant is required to estimate the probability that fish originated 
from lake A, and to indicate whether they have made a decision regarding the origin of the 
fish. All fish drawn remain visible throughout the task in order to minimize working memory 
demands. Parallel versions were used across the testing sessions to reduce practice effects. 
The variables of interest were the number of draws to decision, as well as the probability 
threshold at decision (i.e., the minimum probability estimate, at which a decision was made 
in favor of the respective lake; a higher probability threshold indicates more cautious 
inference making). 
― The World Health Organization Quality of Life - BREF (WHOQOL-BREF) (Murphy et al., 
2000) was used as a measure of overall life satisfaction. This self-report scale assesses 
quality of life in four domains: physical, psychological, social and environment. Moreover, 
two global items assess overall quality of life and general health satisfaction. 
― The Rosenberg Self-Esteem Scale (von Collani and Herzberg, 2003), a widely used 10-item 
self-report measure, was administered to assess self-esteem.  
― The Beck Cognitive Insight Scale (BCIS) (Beck et al., 2004) measures the ability to distance 
oneself from one’s own ideas and reflect upon their possible fallibility. The 15-item self-
report measure yields two scores reflecting self-reflectiveness and self-certainty. It has been 
suggested (Beck and Warman, 2004) and confirmed in patient studies (Riggs et al., 2012) 
that these cognitive insight indices are related to delusional thinking in particular among 
psychotic symptoms, as they reflect inflexible reasoning styles that support delusional 
beliefs.  
2.2 Interventions 
2.2.1 Experimental intervention 
MCT+ is a manualized intervention that comprises 12 twice-weekly individual therapy sessions. 
Its main goal is to highlight the fallibility of cognition in general and encourage patients to reflect 
on their own thinking styles in relation to symptoms, but also to everyday life. MCT+ has a 
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modular structure. Three introductory modules focus on history taking, introduction to the 
intervention rationale and development of a personal illness model. The major cognitive biases 
described above are each introduced in separate modules, and this knowledge is used in later 
modules to discuss broader topics such as social interaction, mood and stress coping. Other than 
the three introductory modules, presentation of individual modules was not fixed in the present 
study, but rather tailored to the individual needs and metacognitive abilities of the patient as 
judged by the therapist. Thus, it was possible to spend more time on a module, revisit some and 
skip other modules. Sessions lasted approximately 45-60 min. Most sessions included 
homework tasks according to the principles of CBT.  
Therapy was delivered by psychologists with variable expertise (and mostly in various stages of 
their training in psychotherapy) in order to best reflect standard conditions in patient care. All 
therapists received group supervision by a certified psychotherapist. 
 
2.2.2 Control intervention 
In order to match the two patient groups on therapeutic effort, an active control condition was 
used. The latter consisted in CogPack® (Marker, 2003), a computerized cognitive training 
program that targets cognitive dysfunctions commonly encountered in patients with psychosis. 
Treatment was administered individually on personal computers and covered a wide range of 
neuropsychological exercises involving memory, reasoning, selective attention and psychomotor 
speed. Each session lasted approximately 45-60 min. Similarly to MCT+, patients could receive a 
maximum of 12 consecutive sessions.  
2.3 Statistical analyses 
Differences between groups in gender, age, premorbid IQ, baseline symptom severity and 
antipsychotic dose, as well as mean antipsychotic medication dose over the whole study were 
assessed by means of t-tests.  
Both intention-to-treat (ITT) and per protocol (PP) analyses were conducted. For PP analyses, 
participants were required to participate in post-treatment and follow-up assessments, 
respectively. ITT analysis considered data from all participants with available baseline data. 
Multiple imputation was adopted to estimate post-treatment and follow-up scores for non-
completers. Both types of analyses used ANCOVAs to assess differences regarding outcome 
variables between groups at T1 and T2. In each of these ANCOVAS, change score of the 
respective variable (e.g. PSYRATS delusions change score for the primary outcome) was the 
dependent variable. Independent variable was group allocation (MCT+ vs. CogPack®). The 
baseline score of the outcome variable was included as a covariate in the model. The reported 
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results include also gender and IQ as predictors, although conducting analyses without these 
variables led to no changes at all regarding the direction of differences and significance levels. 
Significant results are reported at p<0.05 (two-sided), and statistical trends at p<0.1. Effect sizes 
are expressed using η2partial, whereby .01 is equivalent to a small effect, .06 is equivalent to a 
medium effect and .14 is equivalent to a strong effect (Kinnear and Gray, 2009). 
Sample size calculations performed with Gpower (Erdfelder et al., 1996) indicated that a total 
sample size of 90 would be sufficient to detect an effect in the medium range for the primary 
outcome (η2partial=0.08), for a=0.05 and β=0.20.   
3. Results 
3.1 Sample characteristics 
The two groups did not significantly differ in gender, age, premorbid IQ (as assessed with a 
German vocabulary test (Schmidt and Metzler, 1992)) and years of education (Table 1). About 
one third of patients concurrently participated in the MCT group program (a standard part of 
treatment in our department, see Section 2), and there were no differences between the two 
treatment groups in this regard (MCT+ n=15; CogPack® n=20; χ2(1)=1.35, p=0.25). There were 
also no differences in antipsychotic medication dose either at baseline or in average over the 
whole study period (Table 1).  
There were some baseline differences in symptoms between the two intervention groups, with 
CogPack® patients scoring significantly higher on delusional severity and positive symptoms, 
while patients in the MCT+ group had significantly more negative symptoms (Table 1).  
Assessment data were available for approximately 86% of patients at T1 and 80% at T2 and did 
not significantly differ between the two groups. Attendance rates were significantly different 
between the two groups, which was due to higher early drop-out rates in the CogPack® group. 
Patients who dropped out of treatment early (before the 4th session) had significantly lower 
premorbid IQ (t=1.95, p=0.05), requested less draws to reach a decision in the Fish Task (t=3.57, 
p=0.001), and had higher BCIS self-certainty scores (t=2.04, p=0.04), as well as higher baseline 
disorganization (t=2.01, p=0.05) and excitement scores (t=2.66, p=0.009).   
3.2 Intervention effects 
Changes in outcome variables over time are presented in Table 2. Both ITT and PP analyses 
yielded similar results. There was a significant difference in favor of MCT+ with respect to the 
primary outcome variable, PSYRATS delusion score, at T1 [ITT: p=0.03; PP: F(1,72)=5.89, 
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p=0.02, η2p=0.08]. The same was the case for PANSS item P1 at T1 [ITT: p=0.04; PP: 
F(1,72)=5.19, p=0.03, η2p=0.07].  
Regarding reasoning, there were no differences in draws to conclusion change scores between 
the two groups (p>0.80). However, patients in the MCT+ group demonstrated a trend towards 
greater increase in their probability threshold to decision between baseline and T1 (ITT: p=0.07; 
PP: F(1,68)=3.38, p=0.07, η2p=0.05). Moreover, there was a significant difference in favor of 
MCT+ regarding BCIS self-reflectiveness increase at T1 [ITT: p=0.02; PP: F(1,72)=6.16, p=0.02, 
η2p=0.08].  
Regarding all other outcome variables, there were no significant differences between the two 
groups at T1, although there was a numerical advantage for MCT+ in most cases. The highest 
effect sizes, which bordered a statistical trend in the ITT analyses, were noted for WHOQOL-
BREF environment [ITT: p=0.08; F(1,70)=2.60, p=0.11, η2p=0.04], and for self-esteem as 
assessed with the Rosenberg scale [ITT: p=0.10; F(1,72)=2.50, p=0.12, η2p=0.03]. 
At T2, there were no significant differences between the two groups in any of the 
psychopathology, reasoning or other variables (all p>0.30). In many cases, this was due to the 
fact that patients in the CogPack® group, but not in the MCT+ group, showed further 
improvement between T1 and T2 (see Table 2).  
3.3 Additional analyses 
In order to assess whether concurrent group MCT affected results, we repeated all analyses 
using group MCT participation and its interaction with intervention group as additional 
predictors. The main effect of intervention group (MCT+ vs CogPack®) at T1 remained 
significant for PANSS P1 [ITT: p=0.02; PP: F(1,68)=6.40, p=0.01, η2p=0.09], BCIS self-
reflectiveness score [ITT: p=0.005, PP: F(1,68)=8.56, p=0.005, η2p=0.11], and for PSYRATS 
delusion score [ITT: p=0.04; PP: F(1,68)=7.18, p=0.009, η2p=0.10]. Regarding decision thresholds 
at T1, group MCT participation showed a trend-wise effect [ITT: p=0.07; PP: F(1,68)=3.10, 
p=0.08, η2p=0.05]; the main effect of intervention group was no longer significant. At T2, these 
additional analyses led to no differences compared to the original results.   
We also repeated analyses including only patients who completed at least 4 sessions of either 
intervention. The cut-off of 4 sessions was selected to ensure that patients in the MCT+ group 
would have received at least one session dealing with cognitive biases.  This change generally 
led to an increase of effect sizes in favor of MCT+ at T1: PSYRATS delusions [ITT: p=0.002; PP: 
F(1,59)=12.26, p=0.001, η2p=0.17]; P1 [ITT: p=0.003; PP: F(1,59)=10.92, p=0.002, η2p=0.16]; 
BCIS self-reflectiveness [ITT: p=0.002; PP: F(1,59)=13.1, p=0.001, η2p=0.18]. Moreover, 
significance was achieved at T1 for group differences in PANSS positive symptom improvement 
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[ITT: p=0.02; PP: F(1,59)=6.00, p=0.02, η2p=0.09)], PANSS total score improvement [ITT: p=0.02, 
PP: F(1,59)=6.69, p=0.01, η2p=0.10] and decision threshold increase [at a trend level for ITT: 
p=0.07; PP: F(1,57)=5.33, p=0.03, η2p=0.09]. Results at T2 did not change substantially. 
4. Discussion 
The present study assessed the efficacy of an individualized metacognitive intervention (MCT+) 
compared to an active control, using a randomized controlled rater-blind design. MCT+ led to 
greater improvement regarding delusions and some aspects of cognitive bias in the short term 
(6-week follow-up). At the long-term follow-up 6 months later, there were no differences 
between the two intervention groups.  
The beneficial effects of MCT+ on delusions and (partly) cognitive biases are consistent with 
previous studies on group MCT in a purely group format (Moritz et al., 2014a) and accompanied 
by individual therapy sessions (Moritz et al., 2011). This effect was more pronounced in the 
subset of patients who attended a minimum of 4 sessions of either intervention (although this 
finding should be interpreted with caution, because it resulted from additional analyses that did 
not consider the original randomized patient sample). Importantly, the intervention was 
delivered by therapists who did not always have long experience; five of six therapists were still 
in psychotherapy training. It is possible that, due to its highly structured and manualized format, 
MCT+ might be suitable for low-threshold administration without extensive therapist training. 
This increased applicability might, in turn, improve dissemination in clinical practice, which is 
unfortunately still very low for evidence-based therapies such as CBT in patients with psychosis 
(Haddock et al., 2014).  
The observed effects of MCT+ were only observable at the 6-week follow-up. The pattern of 
results suggests that, although MCT+ led to improvement of delusions and reasoning quite early 
on (6 weeks), patients in the CogPack® group eventually attained the same improvement levels. 
This absence of longer-term effects is not consistent with previous studies on group MCT 
(Moritz et al., 2014a). It is probable that this inconsistency is due to selective floor effects in the 
MCT+ group: As shown in Tables 1 and 2, the randomization process resulted in differences 
between the two groups regarding baseline symptoms, which were lower in MCT+ patients -and, 
in fact, lower than in previous studies by our group (Moritz et al., 2013a; Moritz et al., 2011) and 
others (Favrod et al., 2014; So et al., 2015). This, in combination with the rapid improvement, led 
to very low symptom levels in these patients post-intervention, while the control group may 
have benefited from greater margins for change. Alternatively, it may be that further measures 
are needed to promote sustainability of MCT+ effects, especially in patients with psychosis who 
are known to have impaired memory capacity. The CBT concept of ‘booster sessions’ might be 
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applicable here. Other, more low-threshold, possibilities include online or mobile-phone based 
exercises; our group is currently working on the development of respective applications.  
Surprisingly, we did not observe a significant effect on the number of draws to decision in the 
Fish Task, inconsistent with our previous findings regarding group MCT (Moritz et al., 2013a). 
Table 1 indicates a possible reason for this negative finding: The number of draws to decision in 
the present patient sample was much higher at baseline compared to previous studies by our 
group and others (Moritz et al., 2013a; Moritz et al., 2011; So et al., 2015) on MCT. The Fish task 
is widely used in patient studies in our research center, and group MCT is an integral part of 
standard patient care in our department. Hence, most patients would have had at least some 
superficial contact with the concept of "hasty decisions", which may have biased findings. This is 
only a tentative explanation, since Garety et al. (2015) noted a significant effect of their own 
individualized metacognitive intervention on the number of draws to decision despite a 
similarly high baseline value as in the present study. In any event, MCT+ did have beneficial 
effects on other indices of cognitive bias (decision threshold and BCIS self-reflectiveness). 
However, these too were short-lived suggesting a possible need for 'reminders' in the forms 
discussed above. Interestingly, group differences between groups disappeared when concurrent 
participation in group MCT was considered in analyses, while a trend for the group intervention 
emerged. This may indicate a stronger effect for the group intervention, which focuses more 
explicitly on ‘formal’ aspects of cognitive biases rather than individual delusional content. 
However, this hypothesis needs to be assessed in future studies, as group MCT participation was 
not randomized.  
Apart from a transient effect on WHOQOL-BREF environment factor at T1, we did not note any 
significant effects on quality of life and self-esteem, which may be due to the short follow-up 
period: in a previous trial by our group on group MCT (Moritz et al., 2014b), positive effects of 
MCT on quality of life and self-esteem were visible only at the 3-year follow-up.  
A strength of the present study was that it used a randomized controlled rater-blind design 
while simulating conditions of standard care as well as possible through non-restrictive 
inclusion criteria, a wide range of patient baseline symptom severity and therapist experience, 
and flexibility regarding therapy content. However, there are also limitations that should be 
considered. (1) One limitation results from the significantly lower psychopathology scores of the 
MCT+ group at baseline. This difference between the two intervention groups can be attributed 
to chance, since our randomization plan was analogous to the one successfully implemented in a 
previous clinical trial by our group (Moritz et al., 2014b; Moritz et al., 2013a). Still, and although 
all analyses of clinical variables were adjusted for baseline symptom severity, it complicates 
interpretation of results: apart from issues associated with possible floor effects in the MCT+ 
group or larger regression to the mean in control group that may have confounded between-
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group differences, it is not possible to exclude subtle indirect effects of baseline psychopathology 
on outcomes, e.g. by affecting motivation for treatment, or the establishment of a therapeutic 
relationship. (2) There were significantly lower attendance rates in the CogPack® than in the 
MCT+ group. This is in itself a positive finding, as it reflects better acceptance rates of MCT+, 
confirming findings of previous studies on group MCT (Eichner and Berna, 2016). Moreover, 
attendance rates did not affect re-assessment rates, which were comparable in the two 
intervention groups, such that the validity of statistical analyses was not compromised. 
However, the two intervention groups cannot be considered to be similar regarding therapeutic 
effort. This is not a trivial matter, given the results of a recent meta-analysis on CBT for 
psychosis (Mehl et al., 2015) suggesting that effect sizes in favor of CBT diminish significantly 
when the intervention is not compared against treatment-as-usual, but rather against an active 
control intervention. Thus, this point should be considered when designing future efficacy 
studies for any psychotherapy approach. (3) A final limitation of the present study was that it 
did not include a group MCT arm. Although MCT group participation was considered in analyses, 
it will be an interesting aim for future studies to directly compare the two interventions, in order 
to assess whether the individualized format of MCT+ provides further advantages compared to 
the group training.  
In summary, a short course of individualized metacognitive therapy (MCT+) led to faster 
improvement in delusions and cognitive biases compared to a control intervention. The benefit 
associated with MCT+ disappeared in the long term, which may have been due to floor effects 
but may also indicate the need for regular reviews of therapeutic material after completion of 
the intervention.  
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Figure legends 
Figure 1: CONSORT flow diagram 
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Tables 
Table 1:  Sample description and treatment characteristics  
 
MCT+ CogPack   
 
n mean SD n mean SD t/χ2 p 
Gender (m/f) 21 / 25 
  
30 / 16 
  
3.56 0.09 
Age (years) 
 
36.91 12.5 
 
35.59 13.1 0.50 0.62 
Years of education 
 
11.65 1.7 
 
11.27 2.1 0.94 0.35 
IQ 
 
105.42 12.2 
 
100.91 11.5 1.78 0.08 
Symptoms         
PSYRATS delusions   5.74 5.9  8.50 7.3 2.01 0.05 
PANSS         
P1 (delusions)  2.59 1.3  3.24 1.7 2.05 0.04 
total score  49.78 13.0  49.35 12.8 0.16 0.87 
positive   7.37 3.1  9.33 4.4 2.46 0.02 
negative  10.83 4.8  8.30 2.9 3.06 0.003 
disorganization  5.30 2.2  5.76 2.5 0.92 0.36 
excitement  4.74 1.3  5.17 1.5 1.48 0.14 
depression  6.85 3.1  5.74 2.7 1.83 0.07 
Reasoning style         
Fish Task - draws to decision  4.02 2.8  3.44 2.6 1.02 0.31 
Fish Task - decision threshold  79.22 19.3  78.47 22.5 0.17 0.87 
BCIS self-certainty  13.84 2.8  14.74 2.9 1.48 0.14 
BCIS self-reflectiveness  23.89 4.1  24.29 5.0 0.12 0.68 
Quality of Life & self-esteem         
Rosenberg self-esteem scale  16.82 8.3  19.82 8.2 1.72 0.89 
WHOQOL-BREF          
physical  57.48 20.8  61.43 17.5 0.97 0.36 
psychological  49.29 20.9  56.53 19.3 1.69 0.10 
relations  54.89 21.1  57.27 21.8 0.52 0.60 
environment  66.24 16.7  62.97 19.1 0.86 0.39 
Antipsychotic medication 
      
  
CPZ dose at T0 
 
344.56 424.0 
 
305.49 393.5 0.85 0.40 
mean CPZ dose T0-T2 
 
343.39 310.2 
 
282.83 374.2 0.85 0.40 
Attendance & study adherence 
      
  
number of sessions 
 
8.28 3.5 
 
5.59 4.3 3.28 0.001 
participation at >=4 sessions (y/n) 41/5 
  
29/17 
  
8.60 0.006 
data available at T1 (y/n)* 42 / 4 
  
40 / 9 
  
2.24 0.23 
data available at T2 (y/n)** 39 / 7 
  
35 / 11 
  
1.11 0.43 
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* for all variables, with the following exceptions: Fish Task based outcomes (n=40 and n=36 
cases for MCT+ and CogPack®, respectively);  WHOQOL-BREF (n=42 and n=35 cases for 
MCT+ and CogPack®, respectively). 
** for all variables, with the following exceptions: Fish Task based outcomes (n=37 and n=35 
cases for MCT+ and CogPack®, respectively); BCIS,  WHOQOL-BREF and Rosenberg (n=40 
and n=34 cases for MCT+ and CogPack®, respectively). 
  
16 
 
Table 2: Outcomes per intervention group and time point. Means and standard deviations (in brackets). Symbols indicate the significance levels for the 
comparison T0-T1 and T1-T2 in each group separately. For between-group comparisons, please refer to the Results section.  
 
MCT+ CogPack 
 
T0 
 
 
T1  
(within-subject 
change from T0)  
T2  
(within-subject 
change from T1) 
T0 
 
 
T1  
(within-subject 
change from T0)  
T2  
(within-subject 
change from T1) 
Symptoms 
            PSYRATS delusions  5.74 (5.9) 3.48** (5.1)** 5.05 (6.6) 8.50 (7.3) 7.43 (7.1) § 5.60 (7.0)* 
PANSS 
            
P1 (delusions) 2.59 (1.3) 1.88 (1.0)*** 2.10 (1.4) 3.24 (1.7) 2.68 (1.5)** 2.34 (1.6)* 
total score 49.78 (13.0) 43.31 (9.2)*** 43.85 (12.8) 49.35 (12.8) 45.43 (11.0)** 45.00 (12.1) 
positive  7.37 (3.1) 6.00 (2.6)*** 6.23 (3.1) 9.33 (4.4) 7.70 (3.5)** 7.66 (3.4) 
negative 10.83 (4.8) 9.64 (4.7)* 9.35 (3.9) 8.30 (2.9) 8.24 (3.3)* 8.37 (3.0) 
disorganization 5.30 (2.2) 4.50 (1.7)** 4.58 (2.0) 5.76 (2.5) 4.84 (1.9) 4.91 (2.6) 
excitement 4.74 (1.3) 4.45 (0.9) 4.38 (0.8) 5.17 (1.5) 4.92 (1.6) 4.94 (1.7) 
depression 6.85 (3.1) 5.76 (2.6)* 5.85 (3.3) 5.74 (2.7) 5.49 (2.5) 5.23 (3.0) 
Reasoning Style 
            
Fish Task - draws to decision 4.02 (2.8) 4.10 (2.3) 4.19 (2.4) 3.44 (2.6) 4.22 (2.9) 4.49 (2.9) 
Fish Task - decision threshold 79.22 (19.3) 83.69 (18.3) § 82.81 (18.8) 78.47 (22.5) 74.08 (28.0) 84.31 (19.6) 
BCIS self-certainty 13.84 (2.8) 13.98 (2.5) 14.14 (2.8) 14.74 (2.9) 14.08 (2.8) 13.96 (2.4) 
BCIS self-reflectiveness 23.89 (4.1) 24.76 (4.4)* 23.28 (4.6)* 24.29 (5.0) 23.04 (4.5) 22.80 (4.9) 
Quality of Life & self-esteem 
            
Rosenberg self-esteem scale 16.82 (8.3) 20.17 (8.2)*** 20.65 (7.7) 19.82 (8.2) 20.59 (7.4) 21.79 (7.9)* 
WHOQOL-BREF  
            
physical 57.48 (20.8) 63.48 (18.5)* 66.52 (18.1) 61.43 (17.5) 64.59 (18.3) 64.18 (19.3) 
psychological 49.29 (20.9) 56.57 (20.3)* 60.52 (19.0) § 56.53 (19.3) 61.31 (17.8) 61.11 (17.4) 
relations 54.89 (21.1) 59.03 (22.3) 63.13 (19.2) 57.27 (21.8) 57.14 (20.4) 61.74 (17.3) 
environment 66.24 (16.7) 71.00 (13.3)* 72.47 (15.9) 62.97 (19.1)  65.92 (15.5) 67.55 (13.9) 
§ p<0.1, * p<0.05, ** p<0.01 *** P<0.001 
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